(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on genetically engineered and humanized models, AI-enabled preclinical research, CRO outsourcing, precision medicine, advanced imaging and local sourcing.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Animal Model Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Animal Model Market to Reach $2.97 Billion by 2030 as Pharmaceutical R&D Investment Accelerates
The global animal model market is experiencing strong growth, supported by rising pharmaceutical research and development activity, expanding preclinical research programs, and increasing demand for advanced models in drug discovery. The market is projected to grow from $2.07 billion in 2025 to $2.24 billion in 2026, representing a compound annual growth rate (CAGR) of 8.5%.
Historical market growth has been driven by the increasing prevalence of chronic diseases, higher demand for preclinical testing, expansion of pharmaceutical R&D programs, technological advances in laboratory equipment, and continued investment in academic research institutions. Animal models remain essential to the evaluation of therapeutic safety, efficacy, biological mechanisms, and potential clinical outcomes before new treatments advance to human trials.
The animal model market is forecast to reach $2.97 billion by 2030, expanding at a CAGR of 7.3% from 2026. Key growth factors during the forecast period include the adoption of artificial intelligence and machine learning in preclinical studies, the rise of precision medicine, growth in outsourcing to contract research organizations, expansion of genetically modified animal models, and a stronger focus on translational research.
Major animal model market trends include the development of advanced and genetically engineered models, increased use of high-throughput screening, integration of imaging and diagnostic technologies, and broader involvement from contract research organizations. These developments are expected to improve the accuracy, efficiency, and predictive value of preclinical studies while supporting research into complex diseases and next-generation therapies.
Increasing pharmaceutical R&D investment is a major driver of market expansion. Drug discovery and development programs require comprehensive preclinical studies before therapeutic candidates can progress into clinical trials. Spending is rising in response to demand for innovative treatments, the growing burden of complex diseases, and continuing scientific advances. In November 2023, the European Federation of Pharmaceutical Industries and Associations reported that pharmaceutical industry R&D expenditure increased to €50.0 billion in 2023, compared with €47.01 billion in 2022.
Product innovation is also shaping the animal model industry. In January 2024, Charles River Laboratories International introduced NCG mouse strains for oncology and biomedical research. These triple-immunodeficient models lack functional or mature T, B, and natural killer cells and exhibit reduced macrophage and dendritic cell activity. They can accommodate xenograft cells, tissues, and human immune system components, supporting research across oncology, immunology, tumor biology, infectious diseases, graft-versus-host disease, diabetes, regenerative medicine, hematopoiesis, and tissue transplantation.
NCG mice can also support the development of humanized models through the engraftment of peripheral blood mononuclear cells or CD34+ stem cells. This capability enables researchers to more closely replicate human immune responses and conduct more targeted evaluations of potential therapies, particularly in cancer and immunology research.
Strategic partnerships are further advancing preclinical model development. In May 2024, The Jackson Laboratory partnered with AbTherx Inc. to create advanced preclinical models for testing novel therapeutics. The collaboration combines The Jackson Laboratory's translational research and preclinical modeling expertise with AbTherx's next-generation antibody engineering platform. The initiative is intended to accelerate antibody discovery, improve therapeutic testing, and reduce development risks.
North America was the largest region in the animal model market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered by the market include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Animal Type: Mice; Rat; Guinea Pigs; Rabbits; Hamsters; Other Animal Types
2) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); Embryonic Stem Cell Injection; Nuclear Transfer; Other Technologies
3) By Application: Drug Discovery And Development; Basic Research; Other Applications
4) By End User: Research Institutes; Educational Institutes; Pharmaceutical Companies; Contract Research Organizations
Subsegments:
1) By Mice: Inbred Mice; Outbred Mice; Knockout Mice; Transgenic Mice
2) By Rat: Inbred Rats; Outbred Rats; Transgenic Rats; Knockout Rats
3) By Guinea Pigs: Standard Guinea Pigs; Immunodeficient Guinea Pigs
4) By Rabbits: New Zealand White Rabbits; Dutch Belted Rabbits; Other Rabbit Breeds
5) By Hamsters: Syrian Hamsters; Chinese Hamsters
6) By Other Animal Types: Non-Human Primates (Monkeys, Chimpanzees); Dogs; Pigs; Sheep; Ferrets; Other Small Animals (Ferrets, Gerbils)
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment